Johnson & Johnson Profit Tops Estimates as Drug Sales Rise
This article is for subscribers only.
Johnson & Johnson, the world’s biggest maker of health-care products, reported quarterly earnings that topped analysts’ estimates as new cancer and diabetes treatments helped push drug sales higher.
First-quarter earnings, excluding one-time items, were $1.56 a share, compared with the $1.53 average estimate of analysts compiled by Bloomberg.